It wasn't long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn't come together, and the biotech eventually sold to Merck for $11.5 billion. Now, BMS has its eyes on another target, Bloomberg reports.